Ontology highlight
ABSTRACT: Aims
As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations.Methods and results
Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE)-project, we analysed data of 56?804 participants from 7 prospective population-based cohorts across Europe with a maximum follow-up of 24 years. All Lp(a) measurements were performed in the central BiomarCaRE laboratory (Biokit Quantia Lp(a)-Test; Abbott Diagnostics). The three endpoints considered were incident major coronary events (MCE), incident cardiovascular disease (CVD) events, and total mortality. We found lower Lp(a) levels in Northern European cohorts (median 4.9?mg/dL) compared to central (median 7.9?mg/dL) and Southern European cohorts (10.9?mg/dL) (Jonckheere-Terpstra test P?ConclusionIn this large dataset on harmonized Lp(a) determination, we observed regional differences within the European population. Elevated Lp(a) was robustly associated with an increased risk for MCE and CVD in particular among individuals with diabetes. These results may lead to better identification of target populations who might benefit from future Lp(a)-lowering therapies.
SUBMITTER: Waldeyer C
PROVIDER: S-EPMC5837491 | biostudies-literature | 2017 Aug
REPOSITORIES: biostudies-literature
Waldeyer Christoph C Makarova Nataliya N Zeller Tanja T Schnabel Renate B RB Brunner Fabian J FJ Jørgensen Torben T Linneberg Allan A Niiranen Teemu T Salomaa Veikko V Jousilahti Pekka P Yarnell John J Ferrario Marco M MM Veronesi Giovanni G Brambilla Paolo P Signorini Stefano G SG Iacoviello Licia L Costanzo Simona S Giampaoli Simona S Palmieri Luigi L Meisinger Christa C Thorand Barbara B Kee Frank F Koenig Wolfgang W Ojeda Francisco F Kontto Jukka J Landmesser Ulf U Kuulasmaa Kari K Blankenberg Stefan S
European heart journal 20170801 32
<h4>Aims</h4>As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations.<h4>M ...[more]